

Wisconsin State Laboratory of Hygiene

UNIVERSITY OF WISCONSIN-MADISON



An Intro to Culture-Independent Diagnostic Tests for Gastrointestinal Pathogens

Tim Monson, M.S. Microbiologist Supervisor Communicable Disease Division Wisconsin State Laboratory of Hygiene

APHL Annual Meeting May 20, 2015



Objectives of the Session


- Discuss the importance of reviewing and modifying local/state laws for mandatory isolate or clinical material submission
- Describe validation studies and workflow practices within public health laboratories in response to uptake of CIDT testing in clinical laboratories
- Explain current studies to address isolate recovery practices and long-term solutions for culture-independent public health surveillance testing



What is "CIDT"?

- "Culture-Independent Diagnostic Test"
- Any diagnostic test that does not require the culture or isolation of a microorganism in order to arrive at a diagnostic test result
- May be any number of commercially- available or laboratory-derived test methodologies









Commercially Available CIDT's-Multi-target GI Pathogens


- A handful of multi-target assays are available and more are in development
- Variation among the available multi-target
 CIDT's in which GI pathogens are targeted
 (Bacteria only vs bacteria and viruses vs bacteria,
 viruses and parasites)
- Common aspects of multi-target CIDT's:
 - Same day result
 - Molecular/ PCR-based

Devices with GI Panels in Development or FDA Clearance Process





BD Max



BioFire FilmArray



GenMark Dx eSensor XT-8



Cepheid GeneXpert



Nanosphere's Verigene **Enteric Pathogens (EP)**

Test



Applied Biocode







BioFire FilmArray® System



- Sample preparation, amplification, detection and analysis combined
- Add patient sample and reagents and walk away
- Detects 22 common bacterial, viral and parasitic GI pathogens
- Low throughput (single sample- can chain 8 instruments to a PC)
- Results in one hour

Prodesse Progastro™ SSCS Assay



- Detects the four common bacterial agents of gastrointestinal disease: Salmonella, Shigella, Campylobacter and Shiga toxin-producing E. coli
- Real time PCR kit run on the Cepheid SmartCycler II platform
- Results in four hours



BD MAX® Enteric Bacterial Panel



- Detects the 4 common enteric bacterial pathogens
- Virus and Parasite panels in development
- PCR-based
- Fully automated; 24 tests
- Flexibility to target pathogen class (B, V or P)
- Result in three hours

Nanosphere Verigene® Enteric Pathogens (EP) Test



- Detects 9 common bacterial and viral GI pathogens
- Combines automated extraction, purification, amplification and hybridization
- Single throughput; can chain up to 8 instruments
- Result in two hours
- Most recent platform to become available



Luminex xTAG GPP



- Both ASR and RUO kits available
- Detects 14-15 common bacterial, viral and parasitic gastrointestinal pathogens
- Bead-based technology
- Higher throughput; 96 well*
- More significant hands-on time
- Results in 5 hrs (~24 tests)



Advantages to CIDT Use

- Generally faster to result than traditional tests
- Classically-trained microbiologists not needed in many cases
- May be more cost-effective than traditional, conventional tests
- Syndromic-based testing approach possible with multi-target tests
- Ability to detect non-cultureable or fastidious pathogens



Advantages to CIDT Use

- Improved sensitivity and specificity?
 - Compared with culture
 - Need to assess the validity of the developer validation studies; specimens and/or isolates used may not have been optimal
- Detection of nonviable organisms*
 - Only advantageous if truly pathogenic or a significant cause of GI illness



Disadvantages to CIDT Use

- Price of some CIDT platforms may be costprohibitive for laboratories
- Loss of culture isolates
 - To clinical laboratories and PHL's for AST
 - To public health for surveillance
- Loss of classical microbiology experience; staff unable to determine when CIDT results don't make sense



Disadvantages to CIDT Use

- Detection of nonviable organisms*
 - Problematic if not significant; not the cause of illness
 - Ineffective for test of cure; patient may shed nonviable organism or organism DNA well after the infection has passed



Considerations of CIDT Results

- Interpretation of results
 - What do the findings mean in relation to the clinical picture of the patient?
 - What is the significance of multiple pathogens detected?
 - How do epidemiologists apply the current reportable conditions guidelines to CIDT results?
 - Confirmed?
 - Suspect?
 - Probable?





PHL Strategies for CIDT

- Partner with clinical laboratories in your jurisdiction
 - Work to ensure isolate/ specimen submission continues
 - Communicate regularly- know who is using CIDT
- Assess impact of clinical lab CIDT implementation on your laboratory
 - Calculate number of additional cultures you will need to perform
 - Pursue funding (grants, general revenues, etc.) to cover rising costs of PH surveillance



PHL Strategies for CIDT

- Partner with epidemiologists
 - Discuss reporting issues
 - Educate them on what results may mean
- Monitor CIDT use and performance
 - What CIDT's have become available?
 - Have there been published performance issues?
- Pursue mandatory specimen submission in your jurisdiction (in addition to isolate submission mandates)
- Partner with CIDT industry representatives



Summary

- There are a number of multi-target CIDT's that have become available for detection of GI pathogens
- These CIDT's offer definite advantages over traditional culture-based testing methods but considerations still must be taken into account when assessing their utility
- PH labs and epidemiologists must adapt to the ever-changing world of clinical diagnostics
- There are strategies PHL can utilize to address and adapt to the effects CIDT have on them